Biotech entity
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention BeiGene, the most common co-covered peer. The 92-day window averages about 0.2 stories each week. Source depth averages 2 original sources per story, versus 3 across the same-window beat baseline.
Last mentioned: Jun 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention BeiGene, the most common co-covered peer. The 92-day window averages about 0.2 stories each week. Source depth averages 2 original sources per story, versus 3 across the same-window beat baseline. The 7.5 average consequence score is above the beat benchmark of 6.3 in the same window. We currently track 2 Biotech stories that mention WuXi Biologics, published between March 19, 2026 and June 18, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 140 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering WuXi Biologics. Shared-story counts are live from our verified record — not editorial picks.
Healthy China 2030 Deadline
Target date for achieving major healthcare and biotech self-sufficiency milestones.
Official Launch
President Xi Jinping unveils the 15th FYP at the National People's Congress.
15th FYP Drafting
Central Committee reviews the initial draft of the 2026-2030 strategic plan.
14th FYP Implementation
Focus on 'Dual Circulation' and initial biotech innovation pivot.
With zero critical findings on its fourth EMA GMP certification, WuXi Biologics now empowers 13 biotech clients to commercialize 19 biologics in Europe. This milestone validates the company's integrated CRDMO model and deepens its competitive moat in the biologics CDMO space.
Source: prnewswire.com · pannaphat.me
President Xi Jinping’s 15th Five-Year Plan (2026-2030) positions biotechnology as a cornerstone of "New Quality Productive Forces," prioritizing domestic innovation and supply chain self-sufficiency. This strategic shift aims to decouple China’s life sciences sector from Western dependencies while accelerating the commercialization of cell and gene therapies.
WuXi Biologics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
